-
Nylon Fibers Given Muscle-Like Bending Properties
Research engineers at MIT designed a process that gives ordinary nylon fibers the ability to bend and flex like artificial muscles.
-
Engineered T-Cell Trial Halted After Participant Dies
A clinical trial testing treatments that modify immune system cells to fight leukemia in adults was stopped after one of the patients died from inflammation in the brain.
-
Partnership Assessing Nerve Stimulation Bleeding Device
The Feinstein Institute for Medical Research and Global Good Fund are evaluating an electronic device that stimulates nerves to stop bleeding, as a way to control postpartum hemorrhage
-
Targeted Leukemia Drugs Sharply Raising Costs of Care
Drugs directly attacking cancer cell growth show high remission rates with a common form of leukemia, but a new study suggests the high costs of these drugs could impose difficult economic burdens on patients and the health care system.
-
Algae Feed Proposed to Enrich Farm Salmon Fatty Acids
A developer of feeds for farmed salmon says its algae-based feed supplements could arrest the sharp decline in omega-3 fatty acids discovered in a recent study.
-
Novartis Acquires Sickle-Cell Drug Developer
Drug maker Novartis is acquiring Selexys Pharmaceuticals Corp., a developer of treatments for pain episodes associated with sickle cell disease, for $665 million.
-
Nanotech Material Found Having Anti-Bacterial Properties
A synthetic porous material developed to deliver drugs to the skin was shown in lab tests to prevent the growth of bacteria on its surfaces.
-
Large-Scale Cancer Gene Profiling Seen as Feasible
Genomic analysis of tumors, a growing practice for diagnosing cancer in individuals, is shown to be feasible when conducted routinely throughout a cancer care center.
-
Trial Shows Antibody Reduces Days with Migraines
First results from a late-stage clinical trial shows a synthetic antibody reduces the number of days with migraines per month among people with episodic or infrequent migraines.
-
Blood Stem Cell Start-Up Launches, Earns $48.5M Funding
A new enterprise, spun-off from Harvard University stem cell labs, aims to make stem cell transplants from bone marrow safer and more reliable.